


PHARMACEUTICAL 2021

Verona Pharma plc Rank 158 of 409









PHARMACEUTICAL 2021

Verona Pharma plc Rank 158 of 409



The relative strengths and weaknesses of Verona Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verona Pharma plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 201% points. The greatest weakness of Verona Pharma plc is the variable Revenues, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -59%, being 296% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	202,504
Cost of Goods Sold	0
Intangible Assets	545
Liabilities, Current	14,203
Liabilities, Non-Current	5,149
Other Assets	1,050
Other Compr. Net Income	-2,321
Other Expenses	146
Other Liabilities	0
Other Net Income	9,277
Property and Equipment	107
Research and Development	44,505
Revenues	0
Selling, General and Administrative Expense	29,772

Output Variable	Value in 1000 USD
Assets	204,206
Liabilities	19,352
Expenses	74,423
Stockholders Equity	184,854
Net Income	-65,146
Comprehensive Net Income	-66,306
Economic Capital Ratio	-59%

